Results 121 to 130 of about 36,830 (259)

Successful Treatment of IL‐23 Inhibitor–Refractory Nail Psoriasis With Deucravacitinib: A Case Report

JEADV Clinical Practice, EarlyView.
ABSTRACT Nail psoriasis is a prevalent chronic inflammatory disorder that affects the nail unit and is often accompanied by psoriatic skin lesions. It is also more likely to progress to psoriatic arthritis. Here, we report the case of a 57‐year‐old woman who presented with a 3‐year history of nail dystrophy, scaling erythema, and psoriatic plaques on ...
Tianmeng Yan, Xiaoyan Wu, Zhenying Zhang
wiley   +1 more source

Ultrasonographic and power doppler parameters of nails fail to differentiate between onychodystrophy in patients with psoriasis vulgaris or psoriatic arthritis

Advances in Rheumatology
Background Nail involvement is frequent in patients with psoriasis (Pso) and psoriatic arthritis (PsA) and there is a relationship between nail involvement and inflammation of the enthesis.
Anber Ancel Tanaka, Betina Werner, Annelise Correa Bueno Bragatto, Thelma Larocca Skare, Bárbara Stadler   +4 more
doaj   +1 more source

Harnessing Natural Compounds in Psoriasis: Targeting Cellular Pathways for Effective Therapy

Phytotherapy Research, EarlyView.
Natural compounds act on key cellular pathways in psoriasis by suppressing keratinocyte hyperproliferation, modulating Th17/IL‐17‐mediated immune responses, and reducing oxidative stress. These multi‐target effects highlight their potential as safer adjunctive therapies alongside conventional treatments.
Hye Jin Lee, Yu Jin So, Il‐Joo Jo, Ji Yong Jang, Tae Han Yook, Jun Ho Lee, Sung Wook Kim, Kangwook Lee, Soo Jung Park, Gabsik Yang   +9 more
wiley   +1 more source

Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study. [PDF]

J Clin Med, 2022
D'Angelo S, Tirri E, Giardino AM, Mattucci-Cerinic M, Dagna L, Santo L, Ciccia F, Frediani B, Govoni M, Bobbio Pallavicini F, Grembiale RD, Delle Sedie A, Mulè R, Cantatore FP, Foti R, Gremese E, Conigliaro P, Salaffi F, Viapiana O, Cauli A, Giacomelli R, Arcarese L, Guggino G, Russo R, Puenpatom A, Capocotta D, Nacci F, Anelli MG, Picerno V, Binetti C, Iannone F.   +30 more
europepmc   +1 more source

Impact of fibromyalgia on patient acceptable symptom state in Thai patients with spondyloarthritis: A cross‐sectional study

Rheumatology &Autoimmunity, EarlyView.
This cross‐sectional study enrolled Thai patients with spondyloarthritis to assess the prevalence and its impact. Fibromyalgia was present in 5.5% and significantly impaired health‐related quality of life and symptom perception. Low disease activity, good sleep quality, and FS < 3 were independently associated with achieving PASS.
Sittikorn Srivorrapattararkul, Praveena Chiowchanwisawakit   +1 more
wiley   +1 more source

Epidemiology and Treatment of Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis in Germany: A Real-World Evidence Study. [PDF]

Adv Ther, 2021
Grellmann C, Dombrowsky W, Fabricius V, Suruki R, Sheahan A, Joeres L.   +5 more
europepmc   +1 more source

Spatially Profiling Trace Cytokine Signatures From Microscopically Derived Skin Samples to Probe Skin Disease Inflammation

Small Methods, EarlyView.
Inflammatory skin diseases are driven by immune dysregulation and cytokine imbalance. A challenge persists in profiling cytokines in microscopically derived biopsy skin samples due to low protein content. This study introduces a digital SERS immunoassay to simultaneously detect IL‐17A, IL‐22, IL‐23, and TNF at trace concentrations as low as 104 aM. The
Aditya Krishnakumar, Zhen Zhang, Courtney Vedelago, Timothy J. Liu, Yung‐Ching Kao, H. Peter Soyer, Mitchell S. Stark, Snehlata Kumari, Matt Trau, Alain Wuethrich   +9 more
wiley   +1 more source

Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease

The Journal of Dermatology, EarlyView.
ABSTRACT Certain psoriatic disease treatments, including tumor necrosis factor‐α inhibitors (TNFi), increase tuberculosis (TB) risk. Testing for latent TB infection (LTBI) before initiating systemic therapy has been standard practice for psoriasis (PsO) patients; however, updated consensus states routine testing is not required before initiating ...
Luis Puig, Tsen‐Fang Tsai, Enrique R. Soriano, Tina Bhutani, Megan Miller, Alexa P. Kollmeier, Shu Li, Hewei Li, Sarah Ofori, Jeffrey Pawlikowski, Elizabeth Adamson, Melinda Gooderham, Angela Londoño Garcia, Mark Lebwohl, Peter Nash   +14 more
wiley   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

Redefining “Comorbidity” in Dermatology: Beyond Terminology, Lessons From Other Specialties

JEADV Clinical Practice, EarlyView.
Patricia Garbayo‐Salmons, Mireia Moreno   +1 more
wiley   +1 more source